<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541605</url>
  </required_header>
  <id_info>
    <org_study_id>MEMAP1</org_study_id>
    <nct_id>NCT01541605</nct_id>
  </id_info>
  <brief_title>Methylphenidate for the Treatment of Acute Mania</brief_title>
  <official_title>International Randomised Double-blind Placebo-controlled Study on the Initial Treatment of Acute Mania With Methylphenidate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Kluge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Clinical Research Network - CAIBER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the efficacy and safety of methylphenidate in the initial
      treatment of acute mania in patients with bipolar affective disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mania can be regarded as an autoregulatory mechanism to enhance unstable vigilance. There is
      increasing evidence that psychostimulants that increase vigilance may be effective in
      treating mania. However, controlled studies are lacking.

      This is a two-arm, randomised, placebo-controlled, double-blind, parallel, multi-centre phase
      IIIb exploratory study to evaluate the efficacy and safety of methylphenidate in the initial
      treatment of acute mania in patients with bipolar affective disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>manic symptoms as assessed by the Young Mania Rating Scale (YMRS)</measure>
    <time_frame>after 2.5 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG-vigilance as assessed by the Vigilanz Algorhithm Leipzig (VIGALL)</measure>
    <time_frame>after 2.5 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>movements as assessed by actimetry</measure>
    <time_frame>after 2.5 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive performance as assesd with the Screen for Cognitive Impairment in Psychiatry (SCIP)</measure>
    <time_frame>after 2.5 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Mania</condition>
  <arm_group>
    <arm_group_label>methylphenidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate</intervention_name>
    <description>tablets for oral use</description>
    <arm_group_label>methylphenidate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets for oral use</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Inpatients

          2. Written informed consent by patients who are competent to consent to study
             participation.

          3. Diagnosis: manic episode according to the International Classification of Diseases
             10th Revision (ICD-10): F30.0, F30.1, F31.0 or F31.1

          4. Male or female of at least 18 years of age

          5. YMRS total score ≥ 20 and ≤ 45 points

          6. Body mass index (BMI) &gt; 17

          7. Patients must be able to swallow tablets (study drug).

        Exclusion Criteria:

          1. Any other current major psychiatric ICD-10 disorder is an exclusion criterion except
             for the following F90, F17.1, F17.2, F40-F59, F60-F69

          2. Contraindications for treatment with methylphenidate except as noted otherwise

          3. Serious non-psychiatric disease, that may interfere with the objectives of the study
             or with the safety or compliance of the subject, as judged by the investigator

          4. Oral administration of monoaminooxidase (MAO)-inhibitors within two weeks, fluoxetine
             within 6 weeks and of any other antidepressant or primarily psychotropic substance
             except for those specified below within one week before study entry.

          5. Stable treatment with mood stabilisers including lithium, anticonvulsants (e.g.
             valproate, carbamazepine) or antipsychotics (e.g. risperidone, olanzapine) or
             benzodiazepines is NOT an exclusion criterion and will be continued; however, patients
             receiving more than 2 of these substances are NOT eligible for inclusion

          6. Medical history of other disorders of CNS including tics or dyskinesia

          7. Medical history of cardiovascular diseases, severe hypertension, glaucoma,
             hyperfunction of the thyroid

          8. Patients with congenital or acquired long QT syndrome, or with a familiy history of QT
             prolongation, sudden cardiac death or other significant inherited cardiac disorders
             (e.g. family history of hypertrophic cardiomyopathy).

          9. History of Electroconvulsive therapy within the last 3 month

         10. Known alcohol and drug addiction or abuse, except for patients with abstinence &gt; 3
             month. Patients with sporadic abuse of cannabis (products) will not be excluded from
             the study. That is even true with a positive Tetrahydrocannabinol (THC) screen in
             urine.

         11. Pregnant or nursing woman

         12. Concomitant participation in other clinical trials or participation during the 30 days
             prior to screening

         13. Prior participation in this study

         14. Suicidality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Hegerl, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven, campus Kortenberg</name>
      <address>
        <city>Kortenberg</city>
        <zip>3070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Halle</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santiago Apóstol</name>
      <address>
        <city>Vitoria</city>
        <zip>01004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Portugal</country>
  </removed_countries>
  <reference>
    <citation>Kluge M, Hegerl U, Sander C, Dietzel J, Mergl R, Bitter I, Demyttenaere K, Gusmão R, Gonzalez-Pinto A, Perez-Sola V, Vieta E, Juckel G, Zimmermann US, Bauer M, Sienaert P, Quintão S, Edel MA, Bolyos C, Ayuso-Mateos JL, López-García P. Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate. BMC Psychiatry. 2013 Feb 27;13:71. doi: 10.1186/1471-244X-13-71.</citation>
    <PMID>23446109</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Michael Kluge</investigator_full_name>
    <investigator_title>Senior Psychiatrist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

